• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Warfarin beneficial in chronic kidney patients with atrial fibrillation

byRavi Shah
March 6, 2014
in Cardiology, Chronic Disease, Nephrology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Warfarin therapy in chronic kidney disease patients with atrial fibrillation decreased incidence of death, myocardial infarction and stroke at 1-year follow-up.

2. The severity of kidney disease did not correlate to the rate of these outcomes.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Patients presenting with atrial fibrillation (AF) following myocardial infarction are often prescribed warfarin as a preventative measure against thromboembolic events. A subset of these patients also have chronic kidney disease (CKD) potentially complicating their AF management. While patients with CKD and AF have increased risk of thromboembolic events, studies have yielded ambiguous results regarding complications with warfarin use. This study, conducted with Swedish patient data, provides evidence that warfarin therapy decreases 1-year risk of death, myocardial infarction, or ischemic stroke in AF patients at all stages of CKD. There was also no significant difference found in hemorrhagic events between the warfarin and non-warfarin populations. Of note, poor outcome rates were not associated with severity of CKD.

The study’s strengths lie in the large study population, relative completeness of patient information, and thorough control of confounders. Additionally patients in Scandinavian countries have demonstrated therapeutic INRs about 75% of their time on warfarin. Duration of AF, valvular replacement, pulmonary embolism, and deep venous thromboembolism, potentially confounding factors, were not controlled for in this analysis. Furthermore, the follow-up was limited to 1 year, which may be too short to detect complications. Nonetheless, this study supports warfarin use in patients with AF and CKD.

Click to read the study in JAMA

RELATED REPORTS

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation

Adding posterior wall isolation to pulmonary vein isolation not beneficial in ablation for patients with persistent atrial fibrillation — the CAPLA trial

The Apple Watch may have future applications in mental health disorders

Click to read an accompanying editorial in JAMA

Relevant reading: Anticoagulant and antiplatelet therapy in patients with chronic kidney disease: risks versus benefits review.

In-Depth [prospective, observational study]: This study analyzed the occurrence of complications in AF following cardiac events in patients with concomitant CKD. Patient information was collected from the National Inpatient Registry and the System for Enhancement and Development of Evidence Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry in Sweden. A total of 24,317 patients were included in the study of which 5,292 were prescribed warfarin for AF treatment. CKD was stratified into four classes. Rates of death, myocardial infarction and stroke were significantly less at all stages of CKD; eGFR≥60 HR 0.73 (CI95%, 0.65-0.81), eGFR30-60 HR 0.73 (CI95%, 0.66-0.80), eGFR15-30 HR 0.84 (CI95%, 0.70-1.02), eGFR<15 HR 0.57 (CI95%, 0.37-0.86%) in the warfarin cohort. There were no significant differences among hemorrhagic outcome.

More from this author: Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial], Vitamin E associated with slower functional decline in Alzheimer disease [TEAM-AD Trial], PET scans accurately identify amyloid deposition following traumatic brain injury, Bystander CPR positively associated with cardiac arrest survival, Terminal cancer patients hold misconceptions of the role of chemotherapy

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: atrial fibrillationwarfarin
Previous Post

Casino expansion associated with decreased childhood risk of obesity

Next Post

Gender differences in mental health after moving from poverty

RelatedReports

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation
StudyGraphics

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation

January 17, 2023
Patient Basics: Atrial Fibrillation
Cardiology

Adding posterior wall isolation to pulmonary vein isolation not beneficial in ablation for patients with persistent atrial fibrillation — the CAPLA trial

January 16, 2023
Propofol appears safe and effective in procedural sedation for cardioversion
Chronic Disease

The Apple Watch may have future applications in mental health disorders

December 12, 2022
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Cardiology

Patterns of oral anticoagulation use and adherence for atrial fibrillation from 2010-2020

December 21, 2022
Next Post
Home-based depression intervention effective for older African-Americans

Gender differences in mental health after moving from poverty

Blindness and visual impairment decreasing worldwide

Doxycycline may improve vision in nonproliferative diabetic retinopathy

Afatinib shows increased progression-free survival in non-small-cell lung cancer

Rigorousness of Phase III trials for lung cancer may be declining

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options